FDA Awards Absorption Systems Phase II SBIR Grant

Absorption Systems LP has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the U.S. Food and Drug Administration (FDA) to continue development of its CellPort Technologies, the assay platform enabling more specific prediction of potential drug-drug interactions mediated by human drug transport proteins.
CellPort Technologies is believed to become a key component of what is referred to as “Translational Medicine”, the process of translating the results from in vitro assays in model systems into human outcomes in the clinic.
The grant will allow the company to dedicate staff for the next two years to optimize, scale-up and ultimately commercialize the technology.

Absorption Systems, which has facilities near Philadelphia, Pa., and San Diego, Calif., assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. 



Join the discussion